GEVI Form 4: $400,000 Series C buy, $6 warrant for 44,445

Rhea-AI Filing Summary

General Enterprise Ventures (GEVI) — insider Form 4 activity: A reporting person identified as a 10% owner reported multiple transactions. On 09/03/2025, 650,000 shares of Series C Convertible Preferred Stock were converted into 2,166,667 shares of Common Stock, bringing Common Stock beneficial ownership to 2,416,667 shares (direct). On 09/30/2025, the holder purchased 26,667 Series C shares for $400,000 at $15.00 per share and received a warrant to purchase 44,445 Common Stock at an exercise price of $6 per share, expiring 09/30/2030. The Series C is convertible into 3.3333 Common shares per preferred share and has no expiration. An adjustment on 06/30/2025 added 69,007 Series C to offset dilution. Figures reflect GEVI’s 1‑for‑6 reverse split effective 08/28/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BoltRock Holdings LLC

(Last) (First) (Middle)

712 5TH AVENUE

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
General Enterprise Ventures, Inc. [ GEVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		C		2,166,667	A	(1)	2,416,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series C Convertible Preferred Stock	(1)	06/30/2025		J(2)		69,007		(1)	(1)	Common Stock	230,024	(2)	719,007	D
Series C Converticle Preferred Stock	(1)	09/03/2025		C			650,000	(1)	(1)	Common Stock	2,166,667	(1)	69,007	D
Series C Convertible Preferred Stock	(1)	09/30/2025		P		26,667		(1)	(1)	Common Stock	88,890	(3)	95,674	D
Warrant	$6	09/30/2025		P		44,445		(4)	09/30/2030	Common Stock	44,445	(5)	44,445	D

Explanation of Responses:

1. Each share of Series C Convertible Preferred Stock is convertible at any time at the option of the holder into 3.3333 shares of Common Stock. The Series C Convertible Preferred Stock has no expiration date.

2. Represents shares of Series C Convertible Preferred Stock issued to the Reporting Person pursuant to an adjustment under the March 2025 Share Purchase Agreement to offset dilution from subsequent equity issuances.

3. On September 30, 2025, the Reporting Person entered into a securities purchase agreement (the "Securities Purchase Agreement") with the Issuer, pursuant to which the Reporting Person purchased 26,667 shares of Series C Convertible Preferred Stock (the "Series C Shares") for an aggregate purchase price of $400,000 ($15.00 per Series C Share).

4. The Warrant is exercisable at any time by the Reporting Person prior to its expiration.

5. In connection with the execution of the Securities Purchase Agreement, the Reporting Person also executed a common stock purchase warrant agreement (the "Warrant Agreement"), pursuant to which the Issuer issued a warrant to the Reporting Person. The Warrant Agreement entitles the Reporting Person to purchase from the Issuer up to 50% of the number of shares of Common Stock issuable upon full conversion of all the Series C Shares purchased by the Reporting Person, subject to the terms and conditions of the Warrant Agreement.

Remarks:

The number of shares of Common Stock reported herein as beneficially owned by the Reporting Person reflects the 1-for-6 reverse stock split of the Issuer's Common Stock and Series A Preferred Stock effective August 28, 2025.

	/s/ Craig A. Huff, Managing Member	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for GEVI?

A 10% owner converted 650,000 Series C into 2,166,667 Common on 09/03/2025, bought 26,667 Series C on 09/30/2025, and received a warrant for 44,445 Common at $6.

How much did the insider pay for the Series C shares?

The holder paid an aggregate $400,000 at $15.00 per Series C share on 09/30/2025.

What is the conversion ratio for GEVI’s Series C preferred?

Each Series C share converts into 3.3333 shares of Common Stock; the Series C has no expiration.

How many GEVI common shares were owned after the conversion?

Following the 09/03/2025 conversion, the holder reported 2,416,667 Common shares beneficially owned (direct).

What are the warrant terms disclosed?

The warrant allows purchase of 44,445 Common shares at $6 per share, exercisable any time until 09/30/2030.

Were there any adjustments related to dilution?

Yes. On 06/30/2025, 69,007 Series C were issued to offset dilution under a March 2025 Share Purchase Agreement.

Did a reverse stock split affect the reported numbers?

Yes. Amounts reflect a 1‑for‑6 reverse split effective 08/28/2025.